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Stanley G. Dienst, MD,* Krishna D. Valjee, MD,* and Luis H. Toledo-Pereyra, MD, PhD* 
The effect of donor pretreatment on perfused cadaver 
kidney allografts was evaluated in 40 recipients at Henry 
Ford Hospital over a two-year period. Ofthe 40,23 received 
kidneys from donors pretreated with 40 mglK each of 
cyclophosphamide and methylprednisolone during tbe first 
year of the study and upto 70 mg/ K during the second year. 
Our results indicated that donor pretreatment for five to 
eight hours did not consistently improve survival rates in 
pretreated perfused cadaver kidneys following transplanta-
tion. The use of cyclophosphamide for donor pretreatment 
does not prevent the use of continuous perfusion to preserve 
human kidneys. Dosages up to 70 mg/K may be used 
without an apparent increase in acute tubular necrosis or 
significant early loss of renal function. 
A LTHOUGH prolongation of renal allograft survival by 
donor pretreatment with immunosuppressives in animal 
studies has been well established,' these findings have not 
been conclusive in humans. Guttmann and co-workers^ 
have reported improved graft survival following donor 
pretreatment with a combination of cyclophosphamide (40 
mg/K) and methylprednisolone (40 mg/K) five to eight 
hours before harvesting. Zincke and Woods^ have reported 
that cyclophosphamide (60 mg/ K) six to eight hours before 
harvesting followed in three to five hours by the same dose 
of methylprednisolone was also effective. Initially, in our 
Michigan study pretreatment w i th 40 m g / K each of 
cyclophosphamide and methylprednisolone before harvest-
ing showed prolonged graft survival. However, when do-
nors were completely randomized, this augmented graft 
survival was no longer apparent.'' Chatterjee used 70 mg/ K 
of methylprednisolone alone as pretreatment in a control led 
double-blind study and found it to be ineffective in prolong-
ing graft survival.' Jeffery et al in a randomized study used 
cyclophosphamide (100 mg/K) and methylprednisolone 
(70 mg/K) four hours before nephrectomy, but found no 
beneficial effect on graft survival or function.'' The purpose 
ofthis study is to eval uate the effect of donor pretreatment on 
perfused cadaver kidney allografts at Henry Ford Hospital. 
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Patients and Methods 
From June 1973 to July 1975, 23 recipients received kidneys 
from pretreated donors and 17 from nonpretreated. During 
the first year, donors were selected and pretreated five to 
eight hours before nephrectomy with 40 mg/K each of 
cyclophosphamide and methylprednisolone. Afterward, do-
nors were alternated and f inal ly randomized between 
t rea ted and c o n t r o l g roups . First the dosage of 
cyclophosphamide and then of methylprednisolone was 
increased to 70 mg/K after the first year. These drugs were 
given after brain death had been declared. 
Blood pressure of the donors was supported to 100 mm Hg 
systolic wfth dopamine as necessary, and urine output was 
maintained with adequate fluid replacement. All kidneys 
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were preserved at 4°C by hypothermic pulsatile perfusion 
with cryoprecipitated plasma for variable periods of time 
(average of 14 hours). The surgical technique, immunosup-
pression, and postoperative treatment remained constant 
throughout the study. A cooling jacket during transplanta-
tion was used to reduce rewarming time.'"' Azathioprine 5.0 
mg/K was given for one day, then 2.0 mg/K/day for 14 
days, and then 1.0-2.0 mg/K/day adjusted tothe level ofthe 
white blood cell count. Methylprednisolone was given at a 
dose of 1.2 mg/K/day on the day of surgery. Thereafter, the 
total dose was reduced by 2.0 mg each day to a maintenance 
dose of 10 to 30 mg daily. For rejection episodes, patients 
were treated with 1.0 gm of intravenously administered 
methylprednisolone for each of three consecutive days. 
All patients have been at risk for at least six months. The life 
table method of Merrell and Shulman' was used to deter-
mine the graft survival. 
Results 
The actuarial functional survival rate of all recipients who 
received grafts from all pretreated donors at one, two, and 
three years was 48%, 35%, and 30%, respectively (Figure 1). 
These figures do not significantly differ from those for 
nonpretreated group, in which the survival rate atone, two, 
and three years was 47%, 41%, and 41%, respectively 
(Figure 1). Better survival was achieved in the first group in 
which donors had been selected and treated with 40 mg/ K 
of cyclophosphamide and methylprednisolone. The actu-
arial graft survival rates in this group were 63%, 50%, and 
38% at one, two, and three years, respectively (Figure 2). 
Diabetes, the number of previous transplants, and sex did 
not significantly affect the survival rate ofthe grafts in either 
the pretreated or nonpretreated groups. Graft failure due to 
acute tubular necrosis (Figure 1) and infection occurred in 
both treated and control groups equally. 
Discussion 
Overall, donor pretreatment for five to eight hours did not 
consistently improve survival rates in pretreated perfused 
cadaver kidneys following transplantation. These results 
contrast wfth the findings of Guttmann et a/^ and Zincke,^ 
who have had excellent results with pretreated kidneys. 
Three variables must be considered in comparing these 
clinical studies: 1) method of preservation, 2) dosage and 
timingof the pretreatment drugs, and 3) the degree to which 
the kidney donor source has been randomized. 
In Guttmann's series, continuous perfusion was not used. 
The kidneys were cooled by flushing and by surface cooling 
with cold Ringer's lactate. They were then transplanted with 
a maximum of cold preservation time, generally two to six 
hours.^ This routine is supported by studies showing that 
canine kidneys on perfusion or in Collins solution wil l not 
survive as viable grafts in the recipient if the donor is 
pretreated with cyclophosphamide. Asa result ofthis "pres-
ervation intolerance" many programs dependent on perfu-
sion have been discouraged from studying pretreatment. 
However, both Zincke's study^ of the substantial number 
of human k idneys that f u n c t i o n e d w e l l af ter 
cyclophosphamide pretreatment (60 mg/K) and our work 
with good function of 24-hour perfused, pretreated dog 
too 
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Fig.1 
Graft survival in months of kidneys wi th and without acute tubular necrosis (ATN) Left: pretreated kidneys. Right: nonpretreated kidneys. 
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Fig. 2 
Graft survival in months for three different dosage regimens: Selected 
( ), alternated (o o o), and randomized (* A ). 
kidneys (100 mg/K) now tend to minimize the hazard of 
using perfusion to preserve pretreated kidneys. 
The dosage of cyclophosphamide and methylprednisolone 
in these clinical studies has varied from 40 to 80 mg/ K. The 
higher dose of cyclophosphamide has not produced any 
appreciable loss of renal function, and the preferred dose 
has become 5.0 gm or 70 mg/ K for an adult donor. In fact, 
pretreated kidneys provide the recipients with a lower mean 
creatinine level during the first four weeks postoperatively. 
The optimal dosage of methylprednisolone is more equivo-
cal. Although dosages have been increased to as high as 70 
mg/K, a fall in graft survival of pretreated kidneys was 
associated with dosages between 40 and 70 mg/K in both 
this study and in the Michigan study." This may or may not 
be a significant variable. Observations from the use of three 
consecutive daily doses of methylprednisolone system icaliy 
in the dog after transplantation indicate that 70 mg/ K wil l 
produce a consistent loss of function and definite glomerular 
and tubular lesions.'" Therefore, 30 to 50 mg/K of meth-
ylprednisolone would seem to be the appropriate range. 
The third variable in these clinical trials was the randomiz-
ing of kidneys between pretreated and control groups. In 
Guttmann's series, the pretreated donors came from the 
transplant center hospital, while the donors used for controls 
were harvested at other hospitals. In both groups, ice storage 
was the method of preservation.' The grafts were followed 
for three and a half years, and survival between pretreated 
and nontreated was 81% versus 60%. Similady, in the study 
by Zincke at the Mayo Clinic, pretreated kidneys were 
harvested locally, while kidneys harvested by other teams 
and transported long distances were used as the control 
kidneys. All of the kidneys in the Zincke's study were 
preserved by continuous perfusion. The difference in one-
year graft survival between pretreated and nontreated 
groups was more substantial than in Guttmann's series (82% 
versus 43%). 
In both ofthese studies, it is important to question the role of 
donor selection on the results in the control group. Programs 
analyzingtheir kidney procurement program often report an 
increase in the survival of kidneys harvested locally. In the 
Michigan study kidneys were harvested from all over the 
state through its cooperative organ donor program, and an 
effort was made to keep the number of treated and non-
treated patients equal. It is true that pretreated kidneys came 
from donors who were known to be stable and from 
institutions that would transport blood or nodes for typing 
before pretreatment started. However, the statistics of age 
and length of perfusion did not differ between the pre-
treated and nonpretreated groups. The most significant 
indications from the Michigan study were that when the 
assignment of donors was made nonselective as alternate 
cases or was completely randomized, graft survival in the 
control and treated groups was equalized. 
The general scientific criticism of donor pretreatment as an 
applied clinical method for augmenting kidney graft survival 
is that, like other immunological methods which work well 
in small inbred animals, it has notbeen shown to be effective 
in an outbred species. However, Woods has shown moder-
ate prolongation of mongrel canine kidney allografts by 
pretreatment of the donors with procarbazine." We have 
recently shown in dogs that cyclophosphamide and meth-
ylprednisolone acting over 18 to 24 hours in the donor can 
produce very significant extension of graft survival. It re-
mains to be determined whether a protocol with a longer 
donor pretreatment interval such as this is necessary for 
human cadaver kidney doners. 
Conclusions 
1) The use of continuous perfusion preservation for human 
kidneys does not interdict the use of cyclophosphamide 
for donor pretreatment. 
2) Dosages of upto 70 mg/K of cyclophosphamide may be 
used without an apparent increase in acute tubular 
necrosis or significant early loss of renal function. 
3) Further truly randomized clinical trials wil l be necessary 
to establish donor pretreatment as a means of reducing 
rejection and extending human kidney graft survival. 
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